Aurinia Pharmaceuticals (NASDAQ: AUPH) could eventually change how doctors treat kidney failure in lupus patients. If so, buying shares, which have fallen significantly from their peak in March, could prove profit-friendly. Is this stock about to go higher?
Aurinia Pharmaceuticals’ lead product candidate is voclosporin, a drug that is designed to be used alongside CellCept in lupus nephritis (LN) patients.
IMAGE SOURCE: GETTY IMAGES.